MT4 is a monoclonal antibody clone used in CD4+ T-cell research. Developed for flow cytometry applications, MT4 specifically binds to the CD4 receptor (cluster of differentiation 4), a glycoprotein critical for immune cell signaling .
MT4-MMP (Matrix Metalloproteinase-17) is a membrane-bound protease targeted by antibodies like MT4-MMP [EP1270Y]. This recombinant monoclonal antibody detects MT4-MMP in human and mouse samples, with applications in cancer research .
Role in Tumor Progression: MT4-MMP degrades extracellular matrix components (e.g., fibrin) and activates tumor necrosis factor-alpha (TNF-α), promoting tumor invasiveness .
Diagnostic Utility: Validated in immunohistochemistry (IHC) and western blotting, with observed band size at 58 kDa (vs. predicted 67 kDa) .
Therapeutic Potential: Inhibiting MT4-MMP may reduce metastasis in triple-negative breast cancer models .
The MT4/E4 clone targets interferon-alpha 2 (IFN-α2), a cytokine critical for antiviral responses.
| Parameter | Details |
|---|---|
| Host Species | Mouse |
| Isotype | IgG1 κ |
| Applications | Western blot (WB), immunofluorescence (IF), immunoprecipitation (IP) |
| Conjugate Options | HRP, FITC, PE, Alexa Fluor® variants |
| Clinical Relevance | Used in autoimmune disease and cancer immunotherapy research |
A hybridoma-derived MT4 antibody detects fibronectin (FN) in axolotl and newt tissues, aiding regenerative biology research .
| Antibody Name | Target | Host | Applications | Key Research Impact |
|---|---|---|---|---|
| MT4 (Anti-CD4) | CD4 receptor | Mouse | HIV monitoring, immunology | Standardized CD4+ T-cell counting |
| MT4-MMP [EP1270Y] | MMP-17 | Rabbit | Cancer, extracellular matrix | Tumor metastasis mechanisms |
| MT4/E4 | IFN-α2 | Mouse | Viral infection, autoimmunity | Therapeutic cytokine modulation |
| MT4 (Fibronectin) | Fibronectin | Mouse | Developmental biology | Tissue regeneration studies |
Nomenclature Ambiguity: The "MT4" prefix is used across unrelated targets (e.g., CD4, MMP-17), necessitating precise clone and target validation.
Therapeutic Development: Bispecific antibodies (BsAbs) leveraging MT4-like specificity are under investigation for multitarget oncology applications .